The short answer
Olubodun and colleagues published a systematic review of gastroparesis induced by GLP-1 receptor agonists in PLoS One in 2026, describing clinical features, diagnosis, management and outcomes, and characterising it as an under-recognised but clinically important complication.
Key facts
- Systematic review
- Olubodun 2026 (PMID 42594084)
- Journal
- PLoS One
- Described as
- Under-recognised but clinically important
- Covers
- Features, diagnosis, management, outcomes
- Case report
- Singhal 2025 (PMID 41054677)
- Implicated factor
- Rapid dose escalation
What gastroparesis is
Delayed gastric emptying severe enough to cause symptoms in the absence of mechanical obstruction: nausea, vomiting, early fullness, bloating and sometimes weight loss. It is defined by the combination of measurably slow emptying and symptoms attributable to it, not by slow emptying alone.
Why this class produces it
Because delaying gastric emptying is part of how these drugs work. Prolonging fullness and blunting the post-meal glucose rise are intended effects, and they are produced by the same slowing that, taken far enough, becomes the condition. The complication is the mechanism at an extreme rather than an unrelated toxicity.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why that makes the boundary hard to draw
There is no clean line between intended effect and complication when both are the same physiological change. Reduced appetite and early fullness are the point of the treatment and are also gastroparesis symptoms. Distinguishing them depends on severity, persistence and whether the person can maintain adequate intake, which is a clinical judgement rather than a measurement.
The dose escalation observation
Singhal and colleagues reported a case in Cureus in 2025 framed explicitly around the dangers of rapid dose escalation. That is mechanistically coherent: the emptying delay is largest when a dose is new and attenuates with continued exposure, so moving quickly through doses reintroduces the strongest effect repeatedly rather than allowing adaptation.
Why a systematic review matters for a complication like this
Case reports establish that something happens; they cannot say how often or in whom. Pooling them systematically produces a description of typical features, how the diagnosis is reached and what happens subsequently. For an under-recognised complication that is the necessary first step. Before frequency can be estimated, the entity has to be characterised.
What this concerns
Licensed medicines prescribed and monitored clinically, and published clinical literature about them. Nothing supplied on this site is a GLP-1 receptor agonist, affects gastric emptying, or has any bearing on the care of any person.
Frequently asked questions
Why do GLP-1 drugs cause it?
Delaying gastric emptying is part of how they work. The complication is that intended mechanism taken to an extreme.
What does dose escalation have to do with it?
The emptying delay is largest when a dose is new and attenuates with continued exposure, so rapid escalation reintroduces the strongest effect repeatedly.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedOlubodun T et al., Gastroparesis induced by glucagon-like peptide-1 receptor agonists: a systematic review of clinical features, diagnosis, management, and outcomes. PLoS One 2026 (PMID 42594084)pubmed.ncbi.nlm.nih.gov
- PubMedSinghal R et al., Unmasking semaglutide-induced gastroparesis: the dangers of rapid dose escalation in a diabetic patient. Cureus 2025 (PMID 41054677)pubmed.ncbi.nlm.nih.gov
- PubMedShaefer CF Jr et al., User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med 2015 (PMID 26371721)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Same Effect, Past the Point of BenefitSome adverse effects are unrelated toxicities. Others are the drug working too well. The two need different responses, and they get conflated.
- What the SUSTAIN Programme Data ShowedVilsbøll and colleagues evaluated retinopathy data across the SUSTAIN trials. The title places the HbA1c reduction between the drug and the risk.
- Why Fixing Glucose Quickly Can Make the Eye Worse FirstRapid improvement in glycaemic control is associated with transient worsening of retinopathy. It predates every modern diabetes drug.
- A Third Way an Adverse Effect Can AriseSome effects follow not from the drug but from what the drug achieves. Any intervention producing the same change as fast would produce them too.
- Comparing Things That Were Never ComparedWhen no head-to-head exists, a network meta-analysis links treatments through shared comparators. It rests on an assumption worth understanding.